The practical question most people arrive with is simple to say and surprisingly hard to answer: the question of ketamine and treatment-resistant depression: the evidence looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
Anyone comparing the United States programmes will find this decisive: distance is a clinical variable in a treatment requiring six visits in three weeks, which is exactly why remote components deserve serious consideration rather than dismissal. Integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics. Patients researching the United States providers run into this constantly. The gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. It is the first thing to establish about any the United States programme. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. Acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. That is as true in the United States as anywhere else in the country.
The evidence base deserves an honest summary rather than either dismissal or enthusiasm. Multiple randomised controlled trials have found rapid reductions in depressive symptom scores following single and repeated subanaesthetic ketamine infusions, with effects often visible within hours to days rather than weeks, and a separate line of research has examined rapid reduction of suicidal ideation specifically. Those are real findings from real trials. The significant limitations are equally real: many studies are small, blinding is notoriously difficult because the dissociative effect is obvious to participants, follow-up periods are usually short, and the question of what happens over years of maintenance has not been answered. A reasonable reading is that this is a promising and genuinely useful option for a specific population, not a settled standard of care for everyone.
Safety, screening and the limits of the evidence
Approval for esketamine extends to depressive symptoms in adults with major depressive disorder and acute suicidal ideation, a narrow and specific indication rather than a general one. Applied to the United States, the point is this: dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. In the United States the same rule applies: programmes differ enormously in how seriously they take the therapeutic work around the infusion, ranging from employed therapists to a photocopied worksheet. Telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. Nothing about the United States changes that.
Every the United States programme is operating inside the same clinical framework, which runs as follows. Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
How the pieces fit together in practice
In practice this means what people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit. A consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all. For anyone weighing options in the United States, where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. Read against the the United States market, a clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. Any programme presenting six sessions as a complete and finished treatment, without discussing maintenance, has described half of what is involved. Whether a programme titrates the dose according to response and tolerability, or runs a fixed protocol for everyone, is a meaningful difference in how individualised the care actually is.
There is a specific population for whom this conversation is most relevant, and it is narrower than the advertising implies. The trial evidence concentrates on adults with major depressive disorder who have not responded adequately to at least two antidepressant trials at appropriate doses and durations. If someone has never tried a first-line treatment, the reasonable clinical answer is usually to start there, because the evidence is stronger, the cost is lower and the risk profile is better understood. A clinic that agrees to treat anyone who asks, without reference to what has been tried, has replaced clinical judgement with a booking system.
What to do next
A separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. The the United States listings on this page are organised so that this is checkable rather than assumed. The clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell. That holds in the United States as it does everywhere: the subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate. Knowing in advance that the dissociative period is temporary, expected and monitored tends to make it considerably less frightening than encountering it unprepared. It is worth carrying that into every conversation with a the United States provider. Antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. The the United States listings on this page are organised so that this is checkable rather than assumed.
In 2023 the FDA issued a public warning about compounded ketamine products used at home without monitoring, citing risks including sedation, dissociation, airway compromise and the absence of any clinician present if something goes wrong. That warning is the clearest available signal about where the regulatory line sits. Telehealth has a legitimate and useful role in this field for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Using it to mail a dissociative anaesthetic to an unmonitored patient is a different proposition, and the distinction is worth insisting on.
What varies between providers and why it matters
A programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. A standard induction runs to six sessions across two to three weeks, a figure inherited from early trial protocols rather than settled by comparative research. Nothing about the United States changes that. Applied to the United States, the point is this: nausea is common enough that many programmes give an antiemetic pre-emptively rather than waiting to see. Said another way, a single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand. Anyone comparing the United States programmes will find this decisive: weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. That holds in the United States as it does everywhere: because esketamine carries a Risk Evaluation and Mitigation Strategy, it can only be administered at certified centres with at least two hours of post-dose observation.
Preparation shapes the experience more than most people expect. Clinics typically ask patients to avoid solid food for several hours beforehand, largely because of nausea, and to arrange a ride home, because driving is off the table for the remainder of the day. Beyond the logistics, the psychological preparation matters: going in with a settled expectation that the dissociative period is temporary, expected and monitored tends to make it far less alarming than encountering it cold. People who have discussed in advance what they will do if they feel frightened, and who know that the infusion can be slowed or stopped, generally describe a calmer experience than those who have not.
Money, timing and the logistics people underestimate
Randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require. Patients researching the United States providers run into this constantly. In the United States the same rule applies: a dose calculated against body weight and adjusted across a course reflects a different philosophy from one held constant regardless of what the previous session produced. Researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account. That is as true in the United States as anywhere else in the country. Someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. Transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. It is worth carrying that into every conversation with a the United States provider.
The the United States comparison only becomes useful once this is clear. Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
Putting this to use
The useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. For anyone weighing options in the United States, dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. Read against the the United States market, ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. The phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception.
The point of laying all this out is not to argue for or against treatment. It is to make sure that whichever way the decision goes, it is made with the real numbers and the real caveats rather than the marketing version.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.